Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Motzer
    Motzer
  2. De La Cruz
    De La Cruz
  3. De Stanchina
    De Stanchina
  4. Koche
    Koche
  5. Patel
    Patel
  6. Rahnamay Farnoud
    Rahnamay Farnoud
  7. Rosenberg
    Rosenberg
  8. Shah
    Shah
  9. Tap
    Tap
  10. Yu
    Yu

Groups

  1. Department of Medicine (8)
  2. Solid Tumor Oncology Division (7)
  3. Genitourinary Oncology Service (3)
  4. GSK Faculty (2)
  5. Surgery (2)
  6. Thoracic Oncology (2)
  7. Center for Hematologic Malignancies (1)
  8. Executive Committee, Center for Hematologic Malignancies (1)
  9. GDMT, Surgery (1)
  10. Gynecology Disease Management Team (1)
Search Within
  1. "2016"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (1)
Groups
  1. Department of Medicine (8)
  2. Solid Tumor Oncology Division (7)
  3. Genitourinary Oncology Service (3)
  4. GSK Faculty (2)
  5. Surgery (2)
  6. Thoracic Oncology (2)

More Groups

People
  1. Robert Motzer (2)
  2. Amit Sinha (1)
  3. Aniruddha Deshpande (1)
  4. Anthony De La Cruz (1)
  5. Chun-Wei Chen (1)
  6. Elisa De Stanchina (1)

More People

Years
  1. 2016 (12)
Publishers
  1. S. Karger AG (12)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey
    Meeting Abstract

    Schostak, M.; Oh, W. K.; Tombal, B.; Delacruz, A.; Tomlinson, I.; Ripley, A. V.; Drudge-Coates, L.; Mastris, K.; O'Sullivan, J. M.; Shore, N. D.
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Nivolumab monotherapy in metastatic urothelial cancer (mUC): Efficacy (by PD-L1 expression) and safety results from the CheckMate 032 study
    Meeting Abstract

    Jaeger, D.; Sharma, P.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; Morse, M.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Plimack, E. R.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Improvements in quality of life and overall survival in patients with advanced renal cell carcinoma treated with nivolumab vs everolimus in the phase Ill CheckMate 025 study
    Meeting Abstract

    Grünwald, V.; Cella, D.; Nathan, P.; Doan, J.; Dastahi, H.; Taylor, F.; Bennett, B.; DeRosa, M.; Berry, S.; Broglio, K.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Synergistic inhibition of chromatin modifiers reverses a leukemogenic gene expression program in NPM1 mutant leukemia
    Meeting Abstract

    Kühn, M. W. M.; Song, E.; Feng, Z.; Sinha, A.; Chen, C. W.; Deshpande, A. J.; Cusan, M.; Farnoud, N. R.; Koche, R. P.; Bradner, J. E.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Introducing hyperthermic intraperitoneal chemotherapy into gynecological oncology practice - Feasibility and safety considerations: Single-center experience
    Journal Article

    Abramian, A.; Zivanovic, O.; Kuhn, W.; Weber, S.; Schaefer, N.; Keyver-Paik, M. D.; Kiefer, N.
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Kreppel, D.; Bscheider, M.; Bek, S.; Fischer, J.; Schmickl, M.; Ruland, J.; van den Brink, M.; Peschel, C.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (Dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts)
    Meeting Abstract

    Tap, W.; Jones, R. L.; Chmelowski, B.; Elias, A. A.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Meeting Abstract

    Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 22965270 Unknown
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG